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Introduction
Chronic venous disease (CVD) is an insufficiency of
peripheral veins caused by their partial or total
obstruction,  endothelial distension and functional dis-
orders. Chronic venous disease is one of the most
common diseases [1]. It is  a significant social, medical
and economic problem [2]. CVD   of lower limbs is
frequent among Western populations  [3,4].
Manifestations of  chronic venous disorders of
lower limbs  include: teleangiectases, varicose veins,
edema, trophic  changes  and  chronic leg  ulceration.
More advanced abnormalities  of vasculature system
such as: edema,  skin  changes and ulcerations are
called chronic venous insufficiency (CVI) [5].
Implementation of the international classification
system (CEAP) (the clinical class – C, the ethiology – E,
the anatomical – A, the pathophysiology  – P),  created
by American Venous Forum, describes  occurrence and
intensity of venous pathology, and it  is a significant
progress of chronic venous disorders characterization
[5,6]. Thanks to the international CEAP classification the
identification and treatment of CDV is easier. 
Despite  numerous research about  the pathophysi-
ology of CVD the underlying etiology remains not
well understood. The aim of this study is to present
new views about the CVD pathophysiology.  In this
article we try to present the inflammatory process as
the major cause of CVD.  
Pathophysiology 
The reason of the majority of  chronic venous  disease
symptoms is prolonged exposure to venous hyperten-
sion caused by venous wall abnormalities and valvular
incompetence [7].
The venous hypertension and outflow disorders
may be caused by process which leads to pathological
changes of the venous wall. Development of venous
hypertension is caused by reflux through incompetent
venous valves [8]. Reflux of blood can be present in
deep veins of lower limbs, superficial veins of lower
limbs and perforator veins of lower limbs. Venous
reflux  is one of the major  mechanism responsible for
development of venous hypertension [9]. A lot of
research about  the etiology of venous valves 
incompetence have been done.  One of them assume,
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lar incompetence [10]. Susceptibility of   the venous
wall for stretching  mainly depends on the smooth
muscles and connective tissue fibres content in tunica
media.  It's known that intracellular matrix alterations
of  the venous wall is the cause of  the  development of
CVD [11-13]. The property qualitative and quantita-
tive  composition  of the intracellular matrix is the con-
dition of the correctly building and integrality of the
venous wall. Collagen and elastin are  venous wall
proteins, that play the major role in maintenance of an
appropriate resilience and  endurance of the venous
wall [14-16].  Glycosaminoglycans constitute structure
of intracellular matrix and thanks to interaction with
the other components they influence on the venous
wall properties. There are  reports that present connec-
tions between  smooth muscles and elastin fibers.
These connections are significant for venous
endurance when venous pressure is elevated. In vari-
cose veins alterations of elastic fibers  structure are
present and they are separated from smooth muscle
fibers [17]. A deficiency of type III collagen was
observed in CVD patients  [18].  
Recent studies suggest that proteinases released by
inflammatory infiltration cells, may be responsible for
the venous wall hypertrophy. Inflammatory infiltration
cells  cause matrix metalloproteinase (MMP) activa-
tion and collagen dissolution in extracellular matrix.
Moreover, activated endothelial cells release trans-
forming growth factor-β (TGF-β), which causes
migration of muscularis cells and their proliferation 
in tunica intima [19]. The long-lasting secretion of 
TGF-β induces   MMP and tissue inhibitor of metallo-
protease (TIMP) releasing [20]. The balance disorder
between MMP and TIMP also seem to be important in
extracellular matrix damage [21,22]. The other evi-
dence suggest that altered hemodynamics and abnor-
mal blood flow are  main causes of the valvular dam-
age [23]. Next research suggest that  reflux in vessel
lumen is caused by the valvule extension, atrophy of
valve cusp and hemodynamic alterations [24,25]. 
Recent studies has focused on the theory of the
venous  wall and valvular damage as the one of the major
cause of  the  developmentof CVD, caused by chronic
inflammatory process. Recent advances have  shown that
chronic inflammatory process and  leukocytes – endothe-
lial cells interactions  are involved in vessel lumen dys-
functions, valvular incompetence, reflux, venous hyper-
tension, varicose veins and ulcerations [26].     
Molecular mechanisms involved 
in the inflammatory process
Recent advances in the understanding of CDV focused
on interactions between leukocytes and vascular
endothelial cells [27]. Attention  has focused on the
role of leukocytes in the pathophysiology of changes
of the venous wall structure. The intense  leukocytes
infiltration, mainly macrophages and lymphocytes in
CVD patients was observed [28].  The amounts of
granulocytes, monocytes, macrophages and T lympho-
cytes  increased in the venous wall of veins with the
elevation of the blood pressure [29]. B lymphocytes
also were present [30]. 
Chronic elevation of the blood flow through the
venous pressure and  shear stress alterations, may
cause endothelial cell and leukocytes activation [31-
33]. Investigation of the leukocytes shows that the
most activated leukocytes are  isolated from patients
with venous hypertension [34]. Activation of endothe-
lial cells may be caused by their mechanical extension
and that is linked with pathological blood flow and
shear stress alterations [35]. It is clear that and  shear
stress  is the major factor which affects endothelial cell
functions [36].
The molecular mechanism of leukocytes adhesion
to endothelial cells involves two stages. The first stage
is called "I type activation", and it appears quickly. The
activation consequentions are: endothelial cells con-
striction, selectin expression and von Willebrand fac-
tor (vWf)  releasing. The second stage is called "II type
activation", and involves adhesion molecules,
cytokines and tissue factor [37-39].
The process of leukocytes extravasation can be
divided into four steps: rolling, activation, adhesion
and transendothelial migration [40] (Fig. 1). Extrava-
sation  of lymphocytes involves interaction of cell-
adhesion molecules, their activation and chemokines
activity [41-43]. 
During rolling leukocytes attach loosely to the
endothelium by a  L-selectins and E-selectins, which
tether leukocytes to the endothelial cells [44]. Leuko-
cytes tumbles end-over-end along the endothelium.
Subsequently leukocytes are activated by various
chemoattractants e.g.: interleukin 8 (IL-8), complement
split products, macrophage inflammatory protein  (MP-
1β) and N-formyl peptides. Moreover, hypertension is
the cause of red blood cells  (RBCs) extravasation,
which degradation products are potent chemoattractants
and presumably represent the initial signal for leuko-
cytes. Also hypoxia leads to increased production of
platelet activating factor (PAF), which activate  leuko-
cytes [44,45,46,47]. Binding of these chemoattractants
with leukocytes surface receptors is an activating signal.
In the next step,  shedding of adhesion molecules from
leukocytes surfaces occurs as a result of  proteolytic
enzymes action and they circulate  as a soluble molecule
in plasma [48].  Several studies have shown that plasma
levels of soluble L-selectin  increased in CVD patients
[29]. Plasma levels  of the adhesion molecules (ICAM-
1), endothelial leukocytes adhesion molecule (ECAM-
1), vascular cells adhesion molecule (VCAM-1) were
higher in CVD patients than controls [49]. The acti-
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vating signal induces a conformational changes in the
integrin molecules. Increasing of the integrin mole-
cule affinity for Ig-superfamily adhesion molecules
on the endothelium occurs. The interaction between
integrins and Ig-superfamily adhesion molecules pro-
vides firm adhesion of leukocytes to the endothelial
cells.  Leukocytes  firm  adhesion  triggers their
migration through the endothelium [50]. 
Numerous works have shown the leukocytes seques-
tration in valve cups and in the venous wall in CVD
patients compared with controls [21].  Several studies
confirm the "white cell trapping" hypothesis and mas-
sive leukocytes activation in the microcirculation fol-
lowed  by their migration to subcutaneous tissue [51].
This phenomenon is responsible for production and
releasing of cytotoxic substances which lead to skin
ulceration and also valve cups and the venous wall
destruction [52-55].  Leukocytes produce, accumulate
and release: histamine, tryptase, prostaglandins,
leukotriens and cytokines. Histamine increases endothe-
lial permeability and proliferation of smooth muscle
cells. The evaluation of the amount and localization of
infiltrative cells, shows that they are the most numerous
in the proximal venous wall and in the valve cups [56].
Activated leukocytes migrate through proximal
parts of endothelial cups and venous wall and cause
the supporting elements destruction  and valvular
reconstruction, which may cause the valvular  incom-
petence. Leukocytes through penetration to the skin
and subcutaneous tissue may also trigger trophic
changes and ulcerations [57]. 
Summary
Recent studies have shown that the inflammatory
process plays a significant role in CVD pathophysi-
ology. Reconstructions of the venous wall and
venous valves, associated with their dilatation and
relaxation, are the basic mechanism of the develop-
ment of CVD and it is associated with the inflamma-
tory process on their surface.  Leukocytes activated
during the inflammatory process release proteolytic
enzymes, free radicals and cytokines which are
responsible for the  changes of the venous wall  and
venous valve, and also the development of tissue
destruction and skin changes [58]. Moreover,
inflammatory process in CVD patients secondarily
leads to valvular incompetence, reflux and venous
hypertension which further promote development of
inflammatory reaction. Detailed understanding of
these phenomenon may help with early  CVD treat-
ment, that aim is to inhibit inflammatory process.
That may prevent  complications of CVD develop-
ment. 
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